spacer
home > > autumn 2008 > commitment issues
PUBLICATIONS


Commitment Issues

As with all regulations, some are easier to follow than others. There are always going to be scenarios ‘at the margins’ where any regulation will struggle to define the correct procedure or process for dealing with a specific issue, or may appear to be in conflict with some other aspect of best practice.

This has been amply illustrated within the laboratory sector in recent times, with the delayed implementation of General Chapter <467> Residual Solvents of the United States Pharmacopoeia – National Formulary (USP-NF). This proposed revision to the USP-NF had first been scheduled for introduction on 1st January 2007, only for implementation to be delayed until 1st July 2007, and then further delayed with an implementation date of 1st July 2008.

BACKGROUND TO CHAPTER <467>

The essential rationale behind USP <467> is an attempt to harmonise test standards for residual solvents for medicines sold in the US in accordance with a model already adopted by the European Pharmacopeia. It aims to prescribe standard test methods for three classes of solvent. These are:

  • Class 1 solvents, a defined list of chemicals that are known or suspected to be human carcinogens
  • Class 2 solvents, a defined list known to be animal carcinogens or to exhibit other toxicity
  • Class 3 solvents, a defined list of chemicals having low toxic potential

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Philip Payne is Business Development Manager for RSSL Pharma. He joined from Italian API producer, Steroid, where he was General Manager with responsibility for sales, procurement, production and analysis. Fluent in Italian, French and English, and with broad experience of research and production, Philip now assists RSSL Pharma in promoting its analytical and training services more widely across Europe, in addition to the UK and Ireland.
spacer
Philip Payne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Leading pharma packaging companies commit to supply for Covid-19 fight

The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left behind, no matter what region of the world they live in. Also, the companies will make every effort to support the pharma industry’s’ priorities for overall medication supply in addition to Covid-19 drugs. Each of the three companies manufactures billions of type-1 borosilicate glass vials, the most proven and most widely available material used to store and deliver vaccines around the world. They are making the statement to provide confidence in the global pharmaceutical supply chain in times of uncertainty.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement